Edition:
United Kingdom

People: Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

139.51USD
22 May 2019
Change (% chg)

$1.03 (+0.74%)
Prev Close
$138.48
Open
$138.00
Day's High
$140.11
Day's Low
$137.81
Volume
222,721
Avg. Vol
602,578
52-wk High
$197.00
52-wk Low
$125.84

Nicholson, C.David 

Dr. C. David Nicholson is Chief R&D Officer of the company since March 2015. Dr. Nicholson is the Chief R&D Officer of Allergan and has served in this role since March 2015. He joined Allergan (then known as Actavis) as Senior Vice President, Global Brands R&D in August 2014. Previously, he served as Chief Technology Officer and EVP, R&D for Bayer CropScience from March 2012 to August 2014; Vice President of Licensing and Knowledge Management at Merck from 2009 to December 2011; and Senior Vice President, responsible for Global Project Management and Drug Safety at Schering-Plough from 2007 to 2009. From 1988 to 2007, Dr. Nicholson held various leadership positions at Organon, where he most recently served as Executive Vice President, Research & Development and was a member of the company’s Executive Management Committee. He received a B.Sc. from the University of Manchester and his Ph.D. from the University of Wales.

Basic Compensation

Total Annual Compensation, USD 3,859,660
Restricted Stock Award, USD 7,162,720
Long-Term Incentive Plans, USD --
All Other, USD 30,387
Fiscal Year Total, USD 11,052,800

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --